Special Issue

Antimicrobial and Antibiofilm Activity of Nanomaterials: From Bacteria to Yeast

Message from the Guest Editors

Bacteria and fungal infections negatively impact health, life quality, food production, and transportation. In particular, biofilm-forming microorganisms pose an additional risk in healthcare and food-processing settings. Antimicrobial nanomaterials are a promising approach to combat pathogens and disrupt bacterial and fungal biofilms. Current research highlights antimicrobial nanomaterials' use to detect, prevent, and combat pathogens and biofilms. In addition, some nanomaterials display synergistic effects when combined with antimicrobial drugs and disinfectants. This Special Issue seeks manuscript submissions that expand our understanding of the impact of antimicrobial nanomaterials on microbial cell physiology and structure, biofilms, the microbiome, and antimicrobial drugs/antiseptics/disinfectants. Submissions that address the interactions between antimicrobial nanomaterials and microbial cells are particularly encouraged.

Guest Editors

Dr. Roberto Vazquez-Munoz
University of Connecticut Health Center, Farmington, CT, USA

Dr. Lourdes Bazán-Díaz
Materials Research Institute, National Autonomous University of Mexico, Mexico City, Mexico

Deadline for manuscript submissions

closed (15 October 2024)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/141185

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI